Literature DB >> 17923484

High titers of transmissible spongiform encephalopathy infectivity associated with extremely low levels of PrPSc in vivo.

Rona M Barron1, Susan L Campbell, Declan King, Anne Bellon, Karen E Chapman, R Anthony Williamson, Jean C Manson.   

Abstract

Diagnosis of transmissible spongiform encephalopathy (TSE) disease in humans and ruminants relies on the detection in post-mortem brain tissue of the protease-resistant form of the host glycoprotein PrP. The presence of this abnormal isoform (PrP(Sc)) in tissues is taken as indicative of the presence of TSE infectivity. Here we demonstrate conclusively that high titers of TSE infectivity can be present in brain tissue of animals that show clinical and vacuolar signs of TSE disease but contain low or undetectable levels of PrP(Sc). This work questions the correlation between PrP(Sc) level and the titer of infectivity and shows that tissues containing little or no proteinase K-resistant PrP can be infectious and harbor high titers of TSE infectivity. Reliance on protease-resistant PrP(Sc) as a sole measure of infectivity may therefore in some instances significantly underestimate biological properties of diagnostic samples, thereby undermining efforts to contain and eradicate TSEs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17923484     DOI: 10.1074/jbc.M704329200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  75 in total

1.  Enzymatic digestion of chronic wasting disease prions bound to soil.

Authors:  Samuel E Saunders; Jason C Bartz; Kurt C Vercauteren; Shannon L Bartelt-Hunt
Journal:  Environ Sci Technol       Date:  2010-06-01       Impact factor: 9.028

2.  Lower specific infectivity of protease-resistant prion protein generated in cell-free reactions.

Authors:  Mikael Klingeborn; Brent Race; Kimberly D Meade-White; Bruce Chesebro
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-07       Impact factor: 11.205

3.  Agent-specific Shadoo responses in transmissible encephalopathies.

Authors:  Kohtaro Miyazawa; Laura Manuelidis
Journal:  J Neuroimmune Pharmacol       Date:  2010-01-30       Impact factor: 4.147

4.  Report of the Working Group 'Overall Blood Supply Strategy with Regard to Variant Creutzfeldt-Jakob Disease (vCJD)': Statement on the Development and Implementation of Test Systems Suitable for the Screening of Blood Donors for vCJD - Dated September 17, 2008.

Authors: 
Journal:  Transfus Med Hemother       Date:  2009       Impact factor: 3.747

5.  Rapid chemical decontamination of infectious CJD and scrapie particles parallels treatments known to disrupt microbes and biofilms.

Authors:  Sotirios Botsios; Sarah Tittman; Laura Manuelidis
Journal:  Virulence       Date:  2015       Impact factor: 5.882

6.  Aggregated, wild-type prion protein causes neurological dysfunction and synaptic abnormalities.

Authors:  Roberto Chiesa; Pedro Piccardo; Emiliano Biasini; Bernardino Ghetti; David A Harris
Journal:  J Neurosci       Date:  2008-12-03       Impact factor: 6.167

7.  Highly sensitive, quantitative cell-based assay for prions adsorbed to solid surfaces.

Authors:  Julie Ann Edgeworth; Graham S Jackson; Anthony R Clarke; Charles Weissmann; John Collinge
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-09       Impact factor: 11.205

8.  Environmentally-relevant forms of the prion protein.

Authors:  Samuel E Saunders; Jason C Bartz; Glenn C Telling; Shannon L Bartelt-Hunt
Journal:  Environ Sci Technol       Date:  2008-09-01       Impact factor: 9.028

9.  An enzymatic treatment of soil-bound prions effectively inhibits replication.

Authors:  Samuel E Saunders; Jason C Bartz; Kurt C Vercauteren; Shannon L Bartelt-Hunt
Journal:  Appl Environ Microbiol       Date:  2011-05-13       Impact factor: 4.792

10.  Brain delivery of AAV9 expressing an anti-PrP monovalent antibody delays prion disease in mice.

Authors:  Fabio Moda; Chiara Vimercati; Ilaria Campagnani; Margherita Ruggerone; Giorgio Giaccone; Michela Morbin; Lorena Zentilin; Mauro Giacca; Ileana Zucca; Giuseppe Legname; Fabrizio Tagliavini
Journal:  Prion       Date:  2012-07-30       Impact factor: 3.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.